Search research articles
Contact Us
Filters
Showing results (81-90 of 213) with videos related to
Page
of 22
Sort By:
Targeted Oncology
|
May 21, 2025
Olaparib Monotherapy or in Combination with Abiraterone for the Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) and a BRCA Mutation
Fred Saad, Andrew J Armstrong, Neal Shore, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 30, 2005
Ixabepilone (epothilone B analogue BMS-247550) is active in chemotherapy-naive patients with hormone-refractory prostate cancer: a Southwest Oncology Group trial S0111
Maha Hussain, Catherine M Tangen, Primo N Lara, et al.
Medrxiv : the Preprint Server for Health Sciences
|
May 3, 2023
Factor Structure of the Postpartum Bonding Questionnaire in a US-Based Cohort of Mothers
Andréane Lavallée, Jennifer M Warmingham, Mark A Reimers, et al.
Investigational New Drugs
|
November 5, 2010
Phase II study of cilengitide (EMD 121974, NSC 707544) in patients with non-metastatic castration resistant prostate cancer, NCI-6735. A study by the DOD/PCF prostate cancer clinical trials consortium
Ajjai Alva, Susan Slovin, Stephanie Daignault, et al.
The Journal of Urology
|
January 22, 2008
Neoadjuvant docetaxel and capecitabine in patients with high risk prostate cancer
Judah Friedman, Rodney L Dunn, David Wood, et al.
Clinical Genitourinary Cancer
|
May 27, 2008
A University of Chicago consortium phase II trial of SB-715992 in advanced renal cell cancer
Richard T Lee, Kathleen E Beekman, Maha Hussain, et al.
European Urology
|
October 4, 2020
Prostate-specific Antigen Progression in Enzalutamide-treated Men with Nonmetastatic Castration-resistant Prostate Cancer: Any Rise in Prostate-specific Antigen May Require Closer Monitoring
Fred Saad, Cora N Sternberg, Eleni Efstathiou, et al.
Frontiers in Pharmacology
|
October 21, 2021
Evaluation of Biosafety, Antiobesity, and Endothelial Cells Proliferation Potential of Basil Seed Extract Loaded Organic Solid Lipid Nanoparticle
Pandurangan Subash-Babu, Nada Al-Saran, Ghedeir M Alshammari, et al.
European Journal of Cancer (Oxford, England : 1990)
|
February 8, 2026
Use of concomitant G-CSF in maintaining efficacious dose and safe delivery of docetaxel in combination with darolutamide in ARASENS: A phase III study
Michael Ong, Hiroyoshi Suzuki, Matthew Smith, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 17, 2007
Phase 2 study of ABT-510 in patients with previously untreated advanced renal cell carcinoma
Scot Ebbinghaus, Maha Hussain, Nizar Tannir, et al.
Page
of 22
Search research articles
Search
Showing results (81-90 of 213) with videos related to
Sort By:
Page
of 22
Targeted Oncology
|
May 21, 2025
Olaparib Monotherapy or in Combination with Abiraterone for the Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) and a BRCA Mutation
Fred Saad, Andrew J Armstrong, Neal Shore, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 30, 2005
Ixabepilone (epothilone B analogue BMS-247550) is active in chemotherapy-naive patients with hormone-refractory prostate cancer: a Southwest Oncology Group trial S0111
Maha Hussain, Catherine M Tangen, Primo N Lara, et al.
Medrxiv : the Preprint Server for Health Sciences
|
May 3, 2023
Factor Structure of the Postpartum Bonding Questionnaire in a US-Based Cohort of Mothers
Andréane Lavallée, Jennifer M Warmingham, Mark A Reimers, et al.
Investigational New Drugs
|
November 5, 2010
Phase II study of cilengitide (EMD 121974, NSC 707544) in patients with non-metastatic castration resistant prostate cancer, NCI-6735. A study by the DOD/PCF prostate cancer clinical trials consortium
Ajjai Alva, Susan Slovin, Stephanie Daignault, et al.
The Journal of Urology
|
January 22, 2008
Neoadjuvant docetaxel and capecitabine in patients with high risk prostate cancer
Judah Friedman, Rodney L Dunn, David Wood, et al.
Clinical Genitourinary Cancer
|
May 27, 2008
A University of Chicago consortium phase II trial of SB-715992 in advanced renal cell cancer
Richard T Lee, Kathleen E Beekman, Maha Hussain, et al.
European Urology
|
October 4, 2020
Prostate-specific Antigen Progression in Enzalutamide-treated Men with Nonmetastatic Castration-resistant Prostate Cancer: Any Rise in Prostate-specific Antigen May Require Closer Monitoring
Fred Saad, Cora N Sternberg, Eleni Efstathiou, et al.
Frontiers in Pharmacology
|
October 21, 2021
Evaluation of Biosafety, Antiobesity, and Endothelial Cells Proliferation Potential of Basil Seed Extract Loaded Organic Solid Lipid Nanoparticle
Pandurangan Subash-Babu, Nada Al-Saran, Ghedeir M Alshammari, et al.
European Journal of Cancer (Oxford, England : 1990)
|
February 8, 2026
Use of concomitant G-CSF in maintaining efficacious dose and safe delivery of docetaxel in combination with darolutamide in ARASENS: A phase III study
Michael Ong, Hiroyoshi Suzuki, Matthew Smith, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 17, 2007
Phase 2 study of ABT-510 in patients with previously untreated advanced renal cell carcinoma
Scot Ebbinghaus, Maha Hussain, Nizar Tannir, et al.
Page
of 22